{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-188937","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.777608+00:00","generated_at":"2026-05-31T15:19:00.840745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"DBV reports Q2 net loss $33.1M, cash $66.2M, going concern doubt; VITESSE on track","bullets":["Q2 net loss of $33.1M (US GAAP), basic EPS -$0.34 vs -$0.26 in Q2 2023.","Cash and equivalents $66.2M at June 30, 2024, down from $141.4M at Dec 31, 2023; cash runway extended into Q1 2025.","Substantial doubt about going concern; expects to need additional capital to fund operations.","VITESSE Phase 3 enrollment in 4-7-year-olds on track to complete screening by end of Q3 2024.","Submitted labeling proposal to FDA for COMFORT Toddlers (1-3-year-olds) using EPITOPE data to identify responders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-188937","json":"https://secwatch.observer/filing/0001193125-24-188937.json","markdown":"https://secwatch.observer/filing/0001193125-24-188937.md","text":"https://secwatch.observer/filing/0001193125-24-188937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312524188937/0001193125-24-188937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312524188937/d869824d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:19:00.840745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}